US 11,981,733 B2
LAG-3 antibody, antigen-binding fragment thereof, and pharmaceutical application thereof
Zhuoxiao Cao, Shanghai (CN); Yayuan Fu, Shanghai (CN); Qiyue Hu, Shanghai (CN); Weikang Tao, Shanghai (CN); Lianshan Zhang, Shanghai (CN); and Piaoyang Sun, Jiangsu (CN)
Assigned to Jiangsu Hengrui Medicine Co., Ltd., Jiangsu (CN); and Shanghai Hengrui Pharmaceutical Co., Ltd., Shanghai (CN)
Filed by Jiangsu Hengrui Medicine Co., Ltd., Jiangsu (CN); and Shanghai Hengrui Pharmaceutical Co., Ltd., Shanghai (CN)
Filed on Sep. 17, 2021, as Appl. No. 17/478,497.
Application 17/478,497 is a division of application No. 16/312,174, granted, now 11,155,617, previously published as PCT/CN2017/089492, filed on Jun. 22, 2017.
Claims priority of application No. 201610465386.2 (CN), filed on Jun. 23, 2016.
Prior Publication US 2022/0002405 A1, Jan. 6, 2022
Int. Cl. A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01)
CPC C07K 16/2803 (2013.01) [A61K 39/00 (2013.01); A61K 39/395 (2013.01); A61P 35/00 (2018.01); C07K 16/28 (2013.01); C07K 2317/24 (2013.01); C07K 2317/51 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01)] 20 Claims
 
1. A method for inhibiting the growth of tumor cells in a subject, the method comprising administering to a subject an anti-LAG-3 antibody or the antigen-binding fragment thereof, wherein the anti-LAG-3 antibody or the antigen-binding fragment thereof comprises a heavy chain variable region (VH) comprising complementarity determining regions HCDR1, HCDR2, and HCDR3, and a light chain variable region (VL) comprising complementarity determining regions LCDR1, LCDR2, and LCDR3,
wherein the HCDR1, HCDR2, and HCDR3 are identical to complementarity determining regions of a VH having the sequence of SEQ ID NO: 7 and the LCDR1, LCDR2, and LCDR3 are identical to complementarity determining regions of a VL having the sequence of SEQ ID NO: 8.